Drug Interactions between etrasimod and obecabtagene autoleucel
This report displays the potential drug interactions for the following 2 drugs:
- etrasimod
- obecabtagene autoleucel
Interactions between your drugs
etrasimod obecabtagene autoleucel
Applies to: etrasimod and obecabtagene autoleucel
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration of etrasimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Etrasimod causes reversible sequestration of lymphocytes in lymphoid tissues. When administered daily for 52 weeks, etrasimod produced a mean reduction in peripheral blood lymphocyte count to 45% of baseline values, which may increase the risk of infections. Life-threatening and rare fatal infections have occurred in association with other sphingosine 1-phosphate (S1P) receptor modulators. Decreased lymphocyte counts persist during chronic daily dosing and generally return to normal within 4 to 5 weeks after stopping the medication.
MANAGEMENT: The safety and efficacy of etrasimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Because its pharmacodynamic effects may persist for up to 5 weeks after treatment discontinuation, concomitant use during and within 5 weeks following the last dose of etrasimod with antineoplastic, immunosuppressive, or immune-modulating agents should generally be avoided. If concomitant use within this period is considered necessary, patients should be monitored for infectious complications during this extended period. When switching from drugs with prolonged immune effects to etrasimod, the half-life and mode of action of these drugs must also be considered to avoid unintended additive immunosuppressive effects.
Drug and food interactions
etrasimod food
Applies to: etrasimod
Grapefruit juice may increase the blood levels of etrasimod. You should avoid grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with etrasimod unless directed otherwise by your doctor. Talk to your doctor if you have any questions or concerns. Contact your doctor if your condition changes or you experience increased side effects, such as fever, high temperature or flu-like symptoms, severe headache, confusion, seizures, dizziness, tiredness, lightheadedness, chest pain, shortness of breath, or irregular or abnormal heartbeat, blurriness or shadows in the center of your vision, and nausea, vomiting, abdominal pain, anorexia, or jaundice and/or dark urine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.